Some plants used in traditional medicine to manage sickle cell disease have been validated pharmacologically to ascertain their anti-sickling properties. However, there is no global systematic review of the evidence in support of their use for sickle cell management. This research aimed to conduct a systematic review of the pharmacological evidence to highlight species, genera, and some phytochemicals which could be primed for novel anti-sickling medications. The Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines were used. Articles in English, published from 2000 to 2022 were included in the analysis. The literature search covered 411 publications of which 82 were found to be eligible. More than half (53.65%) of the articles were published from 2016 to 2022. Anti-sickling research from Africa accounted for 86.58% of the publications, with more than half coming from Nigeria, 12.20% from Asia and only 1.22% from Europe. The Fabaceae, Euphorbiaceae, and Annonaceae were the top three plant families whereas Zanthoxylum and Terminalia were the most reported genera. Carica papaya and Terminalia catappa were the most reported species. Sickling reversal ( n = 33/82) and hemoglobin polymerization studies ( n = 29/82) were the most reported assays. Benzoic acid derivatives, butyl stearate, ellagic acid derivatives, and some pentacyclic triterpenoids were the only plant derived compounds validated for anti-sickling activities. A total of 117 plant species with anti-sickling activities were documented. Studies on secondary metabolites with anti-sickling properties to serve as scaffolds for novel drug development for sickle cell management were limited.
INPLASY202440121 A systematic review of validated medicinal plants and their compounds as agents for the management of sickle cell disease Keywords: Haemoglobinopathies; medicinal plants: anti-sick…
Objective: This study evaluated the antimalarial activity of the stem bark extract of Amphimas pterocarpoides , isolated bioactive compounds from its most active fraction, and assessed the interactions of these constituents with the Plasmodium falciparum lactate dehydrogenase (pfLDH) in silico. Methods: The acute oral toxicity of the crude extract was assessed in accordance with OECD Guideline 425. In vitro antiplasmodial and erythrocyte compatibility were determined using SYBR Green and MTT assays, respectively. In vivo antimalarial activity was assessed in Plasmodium berghei -infected mice using Peter’s suppressive and Rane’s curative models. Blind molecular docking analysis was used to predict the compound’s interaction with pfLDH. Results: The extract demonstrated promising antiplasmodial activity against the P. falciparum 3D7, K1, and Dd2 strains (IC 50 = 0.771–1.861 μg/mL) and exhibited favourable RBC compatibility, with CC 50 values >80 μg/mL, comparable to those observed for artesunate. The crude extract showed no signs of toxicity at 2000 mg/kg and exhibited significant chemosuppression (84.64 ± 0.47% and 79.37 ± 0.98%) in both in vivo models. Additionally, the extract prevented Plasmodium-induced weight loss, PCV reduction, and hypothermia. Chromatographic fractionation of the most active fraction yielded three compounds: Betulinic acid, 6-methoxyisofomononetin and daucosterol. All isolates and artesunate exhibited appreciable activity against Plasmodium falciparum strains (IC 50 = 0.25–1.13 μM) with erythrocyte selectivity indices >70. Also, all compounds exhibited more favourable predictive interactions with pfLDH than chloroquine did. Conclusion: The crude extract of A. pterocarpoides showed antimalarial potential against chloroquine-sensitive and resistant Plasmodium falciparum strains. To the best of our knowledge, this is the first report of the antiplasmodial activity of 6-methoxyisoformononetin and its interaction with pfLDH.